Xiidra vs. Restasis vs. Cequa: Prescription Dry Eye Drops Compared
Differences Between Xiidra, Restasis and Cequa
When over-the-counter artificial tears are no longer enough to manage your dry eye symptoms, prescription eye drops can offer longer-lasting relief by targeting the underlying inflammation that drives the condition. Xiidra, Restasis, and Cequa are the three most commonly prescribed drops for dry eye disease, and each works through a different approach. According to a 2024 network meta-analysis comparing prescription dry eye treatments, cyclosporine (Restasis and Cequa) and lifitegrast (Xiidra) demonstrated comparable efficacy for dry eye symptoms with generally similar tolerability profiles (Ophthalmology and Therapy, 2024). At Greenwich Ophthalmology Associates, our dry eye specialists in the greater NY/CT region evaluate your specific type of dry eye to determine which prescription therapy is the best fit. Because dry eye disease can present differently from person to person, a thorough evaluation of the tear film, ocular surface, and meibomian glands helps ensure that treatment targets the specific underlying cause rather than masking symptoms temporarily.
Restasis and Cequa both contain cyclosporine, an immunomodulator that reduces inflammation on the ocular surface. Restasis uses a 0.05% concentration, while Cequa delivers a higher 0.09% concentration. Xiidra contains an entirely different active ingredient called lifitegrast, which blocks a specific inflammatory protein on the surface of the eye. Because Xiidra and the cyclosporine-based drops work through separate pathways, patients who do not respond to one class may benefit from the other. Understanding the root cause of your symptoms is a critical first step, because the most effective treatment for dry eye depends on whether the condition involves insufficient tear production, excessive tear evaporation, or a combination of both mechanisms.
Restasis is formulated as an emulsion, meaning it has a slightly thicker, milky consistency. Cequa uses nanomicellar technology to deliver cyclosporine as a clear solution, which may allow better absorption into the eye tissue. Xiidra is also a clear solution and comes in single-use vials. All three medications are preservative-free in their single-dose packaging. Many patients find that dry eye symptoms fluctuate with environmental factors such as humidity levels, screen time, air conditioning, and seasonal allergens, which is why ongoing monitoring and periodic reassessment of your treatment plan can help maintain lasting comfort.
The dosing regimen for all three drops is the same: one drop in each affected eye, twice per day, approximately twelve hours apart. Consistency is essential because these medications work by gradually reducing chronic inflammation rather than providing immediate symptom relief. Our practice serves patients throughout the greater New York and Connecticut region, and we understand that living with chronic eye discomfort can affect your ability to work, read, drive, and enjoy everyday activities, which is why we take a comprehensive and individualized approach to care.
How Each Prescription Drop Works
Restasis was the first prescription eye drop approved specifically for dry eye disease. Cyclosporine works as a calcineurin inhibitor, suppressing the activation of T-cells that drive chronic inflammation on the ocular surface. By reducing this inflammation, Restasis helps restore the eye's natural ability to produce tears. It has a well-established safety profile backed by decades of clinical use. Learn more on our page about how Restasis works. Identifying contributing factors such as medications, systemic health conditions, hormonal changes, and environmental exposures is an important part of the evaluation process, because addressing these influences alongside direct ocular surface treatment often leads to more sustained improvement.
Cequa contains the same active drug as Restasis but at a higher concentration and in a different delivery vehicle. Its nanomicellar formulation is designed to enhance how well cyclosporine penetrates the tissues of the eye. Like Restasis, Cequa suppresses the T-cell-mediated inflammatory response that reduces tear production. Some patients who did not respond adequately to Restasis may find Cequa more effective. Each patient receives a customized management plan that may evolve over time as symptoms improve or new contributing factors emerge, ensuring that the approach remains aligned with your current needs and goals.
Xiidra works through an entirely different mechanism. Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist, which blocks the interaction between LFA-1 and a protein called ICAM-1 on the eye's surface cells. This interaction is a key step in the inflammatory cascade that causes dry eye symptoms and damage. Clinical trials have demonstrated that Xiidra can improve eye dryness scores and reduce corneal staining. Learn more about Xiidra dosing and effectiveness. The relationship between eyelid health and tear film stability is well established in the clinical literature, and addressing lid margin disease is often a necessary foundation for effective dry eye treatment.
How Long Each Medication Takes to Work
One of the most common questions patients ask is how soon they will notice improvement. Cyclosporine-based drops generally require consistent use for several weeks to months before patients experience meaningful relief. Many patients begin noticing improvement around three months, though some may take up to six months to achieve the full benefit. During this initial period, our dry eye specialists often recommend continuing to use preservative-free artificial tears alongside your prescription drop. Regular follow-up visits allow our team to monitor your progress, evaluate how your ocular surface is responding to treatment, and make adjustments to your care plan as needed to help you achieve the best possible long-term outcome.
Xiidra may begin to improve symptoms somewhat earlier than cyclosporine drops. Some clinical trial participants reported improvement in eye dryness as early as two weeks, although most patients see the greatest benefit by twelve weeks of consistent use. As with cyclosporine drops, results vary from person to person. Dry eye disease is a chronic condition for many patients, and effective long-term management often involves a combination of in-office treatments, prescription therapies, and daily at-home care habits that work together to maintain tear film health and ocular surface comfort.
None of these medications provide instant relief, and temporary discomfort upon instillation is common in the early weeks. If you are not seeing improvement after three to six months of consistent use, your doctor may recommend switching to a different medication or adding complementary treatments such as thermal pulsation therapy for meibomian gland dysfunction.
Side Effects of Each Drop
Because both contain cyclosporine, Restasis and Cequa share similar side effects. The most frequently reported reaction is a burning or stinging sensation upon instillation, which tends to be mild to moderate and often decreases over time. Some patients also experience temporary blurred vision, eye redness, or a feeling of something in the eye.
Xiidra's most distinctive side effect is dysgeusia, an unusual taste sensation that some patients describe as metallic or bitter. This occurs because the drop can drain through the tear ducts into the back of the throat. Other common reactions include instillation site irritation and temporarily reduced visual acuity. Learn more about Xiidra side effects and patient experiences.
While most side effects are mild, you should contact our office if you experience significant eye pain, worsening redness, persistent vision changes, or signs of an allergic reaction such as swelling around the eyes. Your doctor can help determine whether your symptoms are a normal adjustment or a reason to modify your treatment plan.
Frequently Asked Questions
Prescription dry eye drops can be a significant investment. Restasis is currently the most affordable of the three because generic cyclosporine 0.05% is available, which substantially reduces the out-of-pocket cost. Cequa and Xiidra remain brand-name only, and their retail prices tend to be higher. Many manufacturers offer copay assistance cards or patient savings programs that can help offset costs.
Yes, and in most cases we recommend it. Prescription drops work over time to reduce inflammation, while artificial tears provide immediate lubrication and comfort. If you use both, apply your artificial tears at least fifteen minutes before or after your prescription drop to avoid diluting the medication.
There is no single best option for every patient with severe dry eye. Some patients with significant inflammation respond well to the higher-concentration cyclosporine in Cequa, while others see better symptom relief with Xiidra's different mechanism. For severe cases, our dry eye specialists may combine prescription drops with other therapies to achieve the best results.
Generic cyclosporine 0.05% ophthalmic emulsion is available as an alternative to brand-name Restasis, and it can offer significant cost savings. There is currently no generic equivalent for Cequa or Xiidra. Your doctor can discuss whether a generic or alternative formulation is appropriate for your situation.
Switching is common and often successful. Because Xiidra and cyclosporine drops target inflammation through different pathways, a patient who does not respond to one mechanism may improve with the other. Most doctors recommend giving a medication at least three months of consistent use before deciding it is not effective.
What our Patients say
4.8
Reviews
(3645)